Cardiology - Global Cardiology Academy

225-240 of 394

TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
Cardiology
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
Ahmad Masri, MD, MS
- Ahmad Masri, MD, MS
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
CME/CE
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
Amy Mottl, MD, MPH; Prof. Christoph Wanner
0.25 credits
- Amy Mottl, MD, MPH
- Prof. Christoph Wanner
0.25 credits
ECG Markers as Predictors of Adverse Outcomes in COPD: Insights from the IMPACT Trial
ECG Markers as Predictors of Adverse Outcomes in COPD: Insights from the IMPACT Trial
Cardiology
ECG Markers as Predictors of Adverse Outcomes in COPD: Insights from the IMPACT Trial
Raymond Wade, MD
- Raymond Wade, MD
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
CME/CE
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
Riccardo Maria Inciardi, MD, PhD
0.25 credits
- Riccardo Maria Inciardi, MD, PhD
0.25 credits
Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
CME/CE
Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
prof. Hiddo Heerspink; Jennifer B. Green, MD
0.25 credits
- prof. Hiddo Heerspink
- Jennifer B. Green, MD
0.25 credits
Practical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure
Practical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure
CME/CE
Practical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure
Robert J. Mentz, MD, FHFSA, FACC; Piotr Ponikowski, MD, PhD, FESC, FHFA
0.25 credits
- Robert J. Mentz, MD, FHFSA, FACC
- Piotr Ponikowski, MD, PhD, FESC, FHFA
0.25 credits
Improving ATTR-CM Diagnosis: Insights on Heart Failure Phenotypes
Improving ATTR-CM Diagnosis: Insights on Heart Failure Phenotypes
Heart Matters
Improving ATTR-CM Diagnosis: Insights on Heart Failure Phenotypes
Early Initiation of Acoramidis in ATTR-CM: Importance and Long-Term Impacts
Early Initiation of Acoramidis in ATTR-CM: Importance and Long-Term Impacts
Heart Matters
Early Initiation of Acoramidis in ATTR-CM: Importance and Long-Term Impacts
Cracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
Cracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
CME/CE
Cracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
Pam R. Taub, MD, FACC, FASPC; Jan T. Kielstein, MD, FASN, FERA
0.25 credits
- Pam R. Taub, MD, FACC, FASPC
- Jan T. Kielstein, MD, FASN, FERA
0.25 credits
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
Cardiology
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
Akshay S. Desai, MD
- Akshay S. Desai, MD
NYHA FC and Finerenone Response: Clinical Trial Insights
NYHA FC and Finerenone Response: Clinical Trial Insights
Cardiology
NYHA FC and Finerenone Response: Clinical Trial Insights
John W. Ostrominski, MD, MPH
- John W. Ostrominski, MD, MPH
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
Cardiology
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
Akshay S. Desai, MD
- Akshay S. Desai, MD
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
Cardiology
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
Stefan D. Anker, MD, PhD; Mahir Karakas, MD, PhD, MBA
- Stefan D. Anker, MD, PhD
- Mahir Karakas, MD, PhD, MBA
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
Cardiology
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
Jonathan Cunningham, MD
- Jonathan Cunningham, MD
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
Cardiology
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
John W. Ostrominski, MD, MPH
- John W. Ostrominski, MD, MPH
FINE-HEART Pooled Analysis
FINE-HEART Pooled Analysis
Cardiology
FINE-HEART Pooled Analysis
Maria Pabon, MD
- Maria Pabon, MD

15/11